Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)
Control Group: without exposure; patients over 60 years, without diabetes.

C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to classify diabetes CA 19-9 will be taken at every 12 months Blood to biobank will be taken at every 12 months. Biomarkers will be determined comparing metabolite levels in plasma samples from patients diagnosed with pancreatic cancer and diabetic cancer-free patients.

Diabetes Mellitus

Diabetes

Diabetes Mellitus, Type 2

Diabetes type2

Cancer of Pancreas

Pancreas Neoplasm

Pancreas Adenocarcinoma

Pancreatic Cancer

The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly

New Onset of DiabetEs in aSsociation With Pancreatic Cancer

This will be evaluated using yes/no questions on carcinoma ductale, then the data will be summarized in order to determine the incidence.

This will be evaluated using yes/no questions as part of a questionnaire filled out by the doctor who examines the patients.

Will be appraised after collecting and summarizing all the collected medical information.

Measuring the body weight of the patient and the data is recorded in the questionaire.

According to the anwers of the patients recorded on the questionnaire.

According to the physical examinations and laboratory parameters also the anwers of the patients recorded on the questionnaire

Healthcare cost spent on each patient will be calculated by a healthcare economist after the trial is completed.

University of Pecs

Hungarian Pancreatic Study Group (HPSG)

Patients will receive insulin therapy with sitagliptin.

Patients will receive insulin therapy without sitagliptin.

Type 1 Diabetes

sitagliptin

Insulin

Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

The assessment of the change of β cell function in patients with LADA treated with sitagliptin plus insulin by the standardized mixed meal stimulation test and insulin sensitivity by HOMA-IR.
The assessment of the change of insulin sensitivity in LADA patients by sequential insulin infusion with the euglycemic glucose clamp technique.

The change of the frequency of pathogenic Teff (CD4+Th1, Th2, Th17 and CD8+) cells and CD4+CD25+Foxp3+Treg cells before and after sitagliptin treatment in LADA patients.

Effect of sitagliptin on cytokine production of Teff and Treg cells before and after sitagliptin treatment in LADA patients.

Effect of sitagliptin on Foxp3 mRNA expression of Treg cells and RORγT mRNA expression of Th17 cells before and after sitagliptin treatment in LADA patients.

The comparison of glutamic acid decarboxylase 65 (GAD65) reactive interferon-γ-Th1, IL-4-Th2, IL-17-Th17 and IL-10-Treg cells detected by enzyme-linked immunospot (ELISPOT) before and after sitagliptin treatment in LADA patients.

The change of the adiponectin, IL-6, IL-17 and CRP etc. before and after the sitagliptin treatment in LADA patients.

glutamic acid decarboxylase/vēzis

The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne